Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that combining monoammonium glycyrrhizinate/glycine/DL-methionine tablets with 5% carpronium chloride may reduce alopecia areata area more effectively than carpronium chloride alone, particularly in patients with allergic factors.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this animal study, a herbal preparation demonstrated moderate anti-inflammatory and immunomodulating properties, suggesting its potential usefulness for preventing and treating alopecia.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This case report describes ALP elevation in a patient with severe OA that normalized after bilateral knee replacements, highlighting a potential link between OA and ALP levels.

This study found that androgen receptor activation in adult mouse skin reduces β-catenin-induced hair follicle growth and sebaceous gland conversion, highlighting its role in stem cell fate decisions.

This study aimed to enhance the skin penetration of brown algae fucoidan using a Nanostructured Lipid Carrier, achieving a formulation with good physical quality and stability.

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

In this study, a mouse model with a PIK3CA gain-of-function mutation in Schwann cells revealed unique communication with neighboring cells and a glycolytic shift in peripheral nerves, and early alpelisib treatment significantly improved symptoms, though efficacy declined with delayed administration due to limited drug penetration.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

This study found that supplementing with 1.5% α-ketoglutaric acid significantly improved the performance, hair follicle density, and antioxidant capacity in Rex rabbits, potentially by enhancing the Wnt signaling pathway and reducing amino acid catabolism.

This study found that probiotics, specifically the L. plantarum MTCC 1325 strain, may have protective effects against Alzheimer's-like symptoms induced by D-Galactose in animal models, suggesting potential therapeutic use for neurodegenerative disorders.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study found that the expression of androgen receptors is higher in the scalp area affected by androgenetic alopecia, and its expression varies based on different traditional Chinese medicine syndromes.

This article proposes the development of a non-sticky Arnica Hydrogel for hair growth, noting that current hair loss treatments do not provide satisfactory results.

This study indicates that MAGE-11 modulates androgen receptor transcriptional activity through F-box interactions, independent of the activation function 2 pathway, revealing a novel mechanism for androgen receptor regulation.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study reported that patients with alopecia areata have reduced expression of the melanocortin receptor MC2R in their scalp tissues compared to normal scalp, indicating potential involvement in the condition's pathophysiology.

In this study, researchers investigated GAGs from the marine invertebrate Microcosmus exasperatus, finding that its polysaccharides possess antitumoral properties without affecting anticoagulant activity. The unique composition shows potential for cancer treatment when combined with existing therapies in future studies.